Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy

Frontiers in Cell and Developmental Biology

Volumn 2, Issue APR, 2014, Pages

  Ogura, Yuji ^a   Tajrishi, Marjan M ^a   Sato, Shuichi ^a   Hindi, Sajedah M ^a   Kumar, Ashok ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Fibrosis; Inflammation; Macrophages; Matrix metalloproteinases; NF B; Skeletal muscle; TIMPs

Indexed keywords

EID: 85041663818     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2014.00011     Document Type: Review

References (110)

1. Acharya, M. R., Venitz, J., Figg, W. D., and Sparreboom, A. (2004). Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. 7, 195-208. doi: 10.1016/j.drup.2004.04.002
2. Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M., Carathers, M., et al. (2007). Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 117, 889-901. doi: 10.1172/JCI30556
3. Ahtikoski, A. M., Koskinen, S. O., Virtanen, P., Kovanen, V., Risteli, J., and Takala, T. E. (2003). Synthesis and degradation of type IV collagen in rat skeletal muscle during immobilization in shortened and lengthened positions. Acta Physiol. Scand. 177, 473-481. doi: 10.1046/j.1365-201X.2003.01061.x
4. Allamand, V., and Campbell, K. P. (2000). Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum. Mol. Genet. 9, 2459-2467. doi: 10.1093/hmg/9.16.2459
5. Asuthkar, S., Velpula, K. K., Nalla, A. K., Gogineni, V. R., Gondi, C. S., and Rao, J. S. (2013). Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene. doi: 10.1038/onc.2013.151. [Epub ahead of print]
6. Bhatnagar, S., and Kumar, A. (2010). Therapeutic targeting of signaling pathways in muscular dystrophy. J. Mol. Med. (Berl.) 88, 155-166. doi: 10.1007/s00109-009-0550-4
7. Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329. doi: 10.1152/physrev.00028.2001
8. Bobadilla, M., Sainz, N., Rodriguez, J. A., Abizanda, G., Orbe, J., de Martino, A., et al. (2014). MMP-10 Is, Required for efficient, muscle regeneration in mouse, models of injury and muscular, dystrophy. Stem Cells 32, 447-461. doi: 10.1002/stem.1553
9. Brack, A. S., Conboy, I. M., Conboy, M. J., Shen, J., and Rando, T. A. (2008). A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2, 50-59. doi: 10.1016/j.stem.2007.10.006
10. Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., et al. (2002a). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86, 1864-1870. doi: 10.1038/sj.bjc.6600310
11. Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., and Buckels, J. A. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447-3455
12. Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., and Buckels, J. A. (2002b). A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167. doi: 10.1038/sj.bjc.6600446
13. Brown, P. D. (1995). Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv. Enzyme Regul. 35, 293-301. doi: 10.1016/0065-2571(94)00022-U
14. Brown, P. D. (1999). Clinical studies with matrix metalloproteinase inhibitors. APMIS 107, 174-180. doi: 10.1111/j.1699-0463.1999.tb01541.x
15. Campbell, K. P. (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-679. doi: 10.1016/0092-8674(95)90344-5
16. Cerletti, M., Jurga, S., Witczak, C. A., Hirshman, M. F., Shadrach, J. L., Goodyear, L. J., et al. (2008). Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 134, 37-47. doi: 10.1016/j.cell.2008.05.049
17. Chakraborti, S., Mandal, M., Das, S., Mandal, A., and Chakraborti, T. (2003). Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. 253, 269-285. doi: 10.1023/A:1026028303196
18. Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., Anthony, D. C., et al. (1997). Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72, 155-161. doi: 10.1016/S0165-5728(96)00179-8
19. Chu, J. W., Jones, G. T., Tarr, G. P., Phillips, L. V., Wilkins, G. T., van Rij, A. M., et al. (2011). Plasma active matrix metalloproteinase 9 associated to diastolic dysfunction in patients with coronary artery disease. Int. J. Cardiol. 147, 336-338. doi: 10.1016/j.ijcard.2010.12.093
20. Cohn, R. D., and Campbell, K. P. (2000). Molecular basis of muscular dystrophies. Muscle Nerve 23, 1456-1471. doi: 10.1002/1097-4598(200010)23:10%3C1456::AID-MUS2%3E3.3.CO;2-K
21. Corry, D. B., Kiss, A., Song, L. Z., Song, L., Xu, J., Lee, S. H., et al. (2004). Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 18, 995-997. doi: 10.1096/fj.03-1412fje
22. Dahiya, S., Bhatnagar, S., Hindi, S. M., Jiang, C., Paul, P. K., Kuang, S., et al. (2011b). Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice. Hum. Mol. Genet. 20, 4345-4359. doi: 10.1093/hmg/ddr362
23. Dahiya, S., Givvimani, S., Bhatnagar, S., Qipshidze, N., Tyagi, S. C., and Kumar, A. (2011a). Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J. Immunol. 187, 2723-2731. doi: 10.4049/jimmunol.1101342
24. Darabi, R., Santos, F. N., and Perlingeiro, R. C. (2008). The therapeutic potential of embryonic and adult stem cells for skeletal muscle regeneration. Stem Cell Rev. 4, 217-225. doi: 10.1007/s12015-008-9023-3
25. Das, S., Mandal, M., Chakraborti, T., Mandal, A., and Chakraborti, S. (2003). Structure and evolutionary aspects of matrix metalloproteinases: a brief overview. Mol. Cell. Biochem. 253, 31-40. doi: 10.1023/A:1026093016148
26. Davies, J. E., Wang, L., Garcia-Oroz, L., Cook, L. J., Vacher, C., O'Donovan, D. G., et al. (2005). Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 11, 672-677. doi: 10.1038/nm1242
27. Delfin, D. A., Zang, K. E., Schill, K. E., Patel, N. T., Janssen, P. M., Raman, S. V., et al. (2012). Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases. Neuromuscul. Disord. 22, 1006-1114. doi: 10.1016/j.nmd.2012.05.002
28. Dezawa, M., Ishikawa, H., Itokazu, Y., Yoshihara, T., Hoshino, M., Takeda, S., et al. (2005). Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309, 314-317. doi: 10.1126/science.1110364
29. Dove, A. (2002). MMP inhibitors: glimmers of hope amidst clinical failures. Nat. Med. 8:95. doi: 10.1038/nm0202-95
30. Ducharme, A., Frantz, S., Aikawa, M., Rabkin, E., Lindsey, M., Rohde, L. E., et al. (2000). Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62. doi: 10.1172/JCI8768
31. Emery, A. E. (2002). The muscular dystrophies. Lancet 359, 687-695. doi: 10.1016/S0140-6736(02)07815-7
32. Fernandes, K. S., Brum, D. G., Sandrim, V. C., Guerreiro, C. T., Barreira, A. A., and Tanus-Santos, J. E. (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J. Neuroimmunol. 214, 128-131. doi: 10.1016/j.jneuroim.2009.07.004
33. Ferretti, G., Fabi, A., Carlini, P., Papaldo, P., Cordiali Fei, P., Di Cosimo, S., et al. (2005). Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69, 35-43. doi: 10.1159/000087286
34. Fingleton, B. (2007). Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346. doi: 10.2174/138161207779313551
35. Fingleton, B. (2008). MMPs as therapeutic targets-still a viable option? Semin. Cell Dev. Biol. 19, 61-68. doi: 10.1016/j.semcdb.2007.06.006
36. Fukuda, Y., Ishizaki, M., Kudoh, S., Kitaichi, M., and Yamanaka, N. (1998). Localization of matrix metalloproteinases-1,-2, and-9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab. Invest. 78, 687-698
37. Fukushima, K., Nakamura, A., Ueda, H., Yuasa, K., Yoshida, K., Takeda, S., et al. (2007). Activation and localization of matrix metalloproteinase-2 and-9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskelet. Disord. 8:54. doi: 10.1186/1471-2474-8-54
38. Gargioli, C., Coletta, M., De Grandis, F., Cannata, S. M., and Cossu, G. (2008). PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle. Nat. Med. 14, 973-978. doi: 10.1038/nm.1852
39. Giraudo, E., Inoue, M., and Hanahan, D. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114, 623-633. doi: 10.1172/JCI200422087
40. Girgenrath, M., Beermann, M. L., Vishnudas, V. K., Homma, S., and Miller, J. B. (2009). Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol. 65, 47-56. doi: 10.1002/ana.21523
41. Grams, F., Crimmin, M., Hinnes, L., Huxley, P., Pieper, M., Tschesche, H., et al. (1995). Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. Biochemistry 34, 14012-14020. doi: 10.1021/bi00043a007
42. Gum, R., Lengyel, E., Juarez, J., Chen, J. H., Sato, H., Seiki, M., et al. (1996). Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J. Biol. Chem. 271, 10672-10680. doi: 10.1074/jbc.271.18.10672
43. Halade, G. V., Jin, Y. F., and Lindsey, M. L. (2013). Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 139, 32-40. doi: 10.1016/j.pharmthera.2013.03.009
44. Haslett, J. N., Sanoudou, D., Kho, A. T., Bennett, R. R., Greenberg, S. A., Kohane, I. S., et al. (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 99, 15000-15005. doi: 10.1073/pnas.192571199
45. Hindi, S. M., Shin, J., Ogura, Y., Li, H., and Kumar, A. (2013b). Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice. PLoS ONE 8:e72121. doi: 10.1371/journal.pone.0072121
46. Hindi, S. M., Tajrishi, M. M., and Kumar, A. (2013a). Signaling mechanisms in mammalian myoblast fusion. Sci. Signal. 6:re2. doi: 10.1126/scisignal.2003832
47. Hnia, K., Gayraud, J., Hugon, G., Ramonatxo, M., De La Porte, S., Matecki, S., et al. (2008). L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172, 1509-1519. doi: 10.2353/ajpath.2008.071009
48. Hnia, K., Hugon, G., Rivier, F., Masmoudi, A., Mercier, J., and Mornet, D. (2007). Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am. J. Pathol. 170, 633-643. doi: 10.2353/ajpath.2007.060344
49. Hoffman, E. P., Brown, R. H. Jr., and Kunkel, L. M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928. doi: 10.1016/0092-8674(87)90579-4
50. Kherif, S., Lafuma, C., Dehaupas, M., Lachkar, S., Fournier, J. G., Verdiere-Sahuque, M., et al. (1999). Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev. Biol. 205, 158-170. doi: 10.1006/dbio.1998.9107
51. Kjaer, M. (2004). Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol. Rev. 84, 649-698. doi: 10.1152/physrev.00031.2003
52. Koskinen, S. O., Kjaer, M., Mohr, T., Sorensen, F. B., Suuronen, T., and Takala, T. E. (2000). Type IV collagen and its degradation in paralyzed human muscle: effect of functional electrical stimulation. Muscle Nerve 23, 580-589. doi: 10.1002/(SICI)1097-4598(200004)23:4%3C580::AID-MUS18%3E3.0.CO;2-4
53. Kumar, A., Bhatnagar, S., and Kumar, A. (2010). Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am. J. Pathol. 177, 248-260. doi: 10.2353/ajpath.2010.091176
54. Kumar, A., and Boriek, A. M. (2003). Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 17, 386-396. doi: 10.1096/fj.02-0542com
55. Kumar, A., Khandelwal, N., Malya, R., Reid, M. B., and Boriek, A. M. (2004). Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 18, 102-113. doi: 10.1096/fj.03-0453com
56. Ladwig, G. P., Robson, M. C., Liu, R., Kuhn, M. A., Muir, D. F., and Schultz, G. S. (2002). Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 10, 26-37. doi: 10.1046/j.1524-475X.2002.10903.x
57. Lewis, M. P., Machell, J. R., Hunt, N. P., Sinanan, A. C., and Tippett, H. L. (2001). The extracellular matrix of muscle-implications for manipulation of the craniofacial musculature. Eur. J. Oral Sci. 109, 209-221. doi: 10.1034/j.1600-0722.2001.00021.x
58. Li, H., Malhotra, S., and Kumar, A. (2008). Nuclear factor-kappa B signaling in skeletal muscle atrophy. J. Mol. Med. (Berl.) 86, 1113-1126. doi: 10.1007/s00109-008-0373-8
59. Li, H., Mittal, A., Makonchuk, D. Y., Bhatnagar, S., and Kumar, A. (2009b). Matrix metalloproteinase-9 Inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum. Mol. Genet. 18, 2584-2598. doi: 10.1093/hmg/ddp191
60. Li, H., Mittal, A., Paul, P. K., Kumar, M., Srivastava, D. S., Tyagi, S. C., et al. (2009a). Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. J. Biol. Chem. 284, 4439-4450. doi: 10.1074/jbc.M805546200
61. Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., Braybrooke, J. P., Long, L., Gleeson, F., et al. (1999). Phase, I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5, 513-520
62. Martin, M. D., Carter, K. J., Jean-Philippe, S. R., Chang, M., Mobashery, S., Thiolloy, S., et al. (2008). Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 68, 6251-6259. doi: 10.1158/0008-5472.CAN-08-0537
63. Matsumura, K., Zhong, D., Saito, F., Arai, K., Adachi, K., Kawai, H., et al. (2005). Proteolysis of beta-dystroglycan in muscular diseases. Neuromuscul. Disord. 15, 336-341. doi: 10.1016/j.nmd.2005.01.007
64. Michaluk, P., Kolodziej, L., Mioduszewska, B., Wilczynski, G. M., Dzwonek, J., Jaworski, J., et al. (2007). Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J. Biol. Chem. 282, 16036-16041. doi: 10.1074/jbc.M700641200
65. Miyazaki, D., Nakamura, A., Fukushima, K., Yoshida, K., Takeda, S., and Ikeda, S. I. (2011). Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscle reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum. Mol. Genet. 20, 1787-1799. doi: 10.1093/hmg/ddr062
66. Mott, J. D., and Werb, Z. (2004). Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 16, 558-564. doi: 10.1016/j.ceb.2004.07.010
67. Munoz-Valle, J. F., Vazquez-Del Mercado, M., Garcia-Iglesias, T., Orozco-Barocio, G., Bernard-Medina, G., Martinez-Bonilla, G., et al. (2003). T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients. Clin. Exp. Immunol. 131, 377-384. doi: 10.1046/j.1365-2249.2003.02059.x
68. Nadarajah, V. D., van Putten, M., Chaouch, A., Garrood, P., Straub, V., Lochmuller, H., et al. (2011). Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 21, 569-578. doi: 10.1016/j.nmd.2011.05.011
69. Nagase, H., and Woessner, J. F. Jr. (1999). Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494. doi: 10.1074/jbc.274.31.21491
70. Nair, R. R., and Boyd, D. D. (2005). Expression cloning of novel regulators of 92 kDa type IV collagenase expression. Biochem. Soc. Trans. 33(Pt 5), 1135-1136. doi: 10.1042/BST20051135
71. Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., et al. (1998). Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 4, 1101-1109
72. Niebroj-Dobosz, I., Madej-Pilarczyk, A., Marchel, M., Sokolowska, B., and Hausmanowa-Petrusewicz, I. (2009). Matrix metalloproteinases in serum of Emery-Dreifuss muscular dystrophy patients. Acta Biochim. Pol. 56, 717-722
73. Page-McCaw, A., Ewald, A. J., and Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell. Biol. 8, 221-233. doi: 10.1038/nrm2125
74. Parsons, S. L., Watson, S. A., and Steele, R. J. (1997). Phase, I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J. Surg. Oncol. 23, 526-531. doi: 10.1016/S0748-7983(97)93077-8
75. Percival, J. M., Whitehead, N. P., Adams, M. E., Adamo, C. M., Beavo, J. A., and Froehner, S. C. (2012). Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J. Pathol. 228, 77-87. doi: 10.1002/path.4054
76. Pereira, J. A., Matsumura, C. Y., Minatel, E., Marques, M. J., and Santo Neto, H. (2014). Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse. Muscle Nerve. doi: 10.1002/mus.24177. [Epub ahead of print]
77. Pereira, J. A., Taniguti, A. P., Matsumura, C., Marques, M. J., and Neto, H. S. (2012). Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice. Muscle Nerve 46, 400-406. doi: 10.1002/mus.23331
78. Pichavant, C., Gargioli, C., and Tremblay, J. P. (2011). Intramuscular, transplantation of Muscle, precursor cells over-expressing MMP-9 improves transplantation, success. PLoS Curr. 3:RRN1275. doi: 10.1371/currents.RRN1275
79. Porter, J. D., Khanna, S., Kaminski, H. J., Rao, J. S., Merriam, A. P., Richmonds, C. R., et al. (2002). A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum. Mol. Genet. 11, 263-272. doi: 10.1093/hmg/11.3.263
80. Price, F. D., Kuroda, K., and Rudnicki, M. A. (2007). Stem cell based therapies to treat muscular dystrophy. Biochim. Biophys. Acta 1772, 272-283. doi: 10.1016/j.bbadis.2006.08.011
81. Prins, K. W., Humston, J. L., Mehta, A., Tate, V., Ralston, E., and Ervasti, J. M. (2009). Dystrophin is a microtubule-associated protein. J. Cell Biol. 186, 363-369. doi: 10.1083/jcb.200905048
82. Qu, Z., Balkir, L., van Deutekom, J. C., Robbins, P. D., Pruchnic, R., and Huard, J. (1998). Development of approaches to improve cell survival in myoblast transfer therapy. J. Cell Biol. 142, 1257-1267. doi: 10.1083/jcb.142.5.1257
83. Ram, M., Sherer, Y., and Shoenfeld, Y. (2006). Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 26, 299-307. doi: 10.1007/s10875-006-9022-6
84. Rando, T. A. (2001). The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24, 1575-1594. doi: 10.1002/mus.1192
85. Rasmussen, H. S., and McCann, P. P. (1997). Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. 75, 69-75. doi: 10.1016/S0163-7258(97)00023-5
86. Rayment, E. A., Upton, Z., and Shooter, G. K. (2008). Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br. J. Dermatol. 158, 951-961. doi: 10.1111/j.1365-2133.2008.08462.x
87. Renkiewicz, R., Qiu, L., Lesch, C., Sun, X., Devalaraja, R., Cody, T., et al. (2003). Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 48, 1742-1749. doi: 10.1002/art.11030
88. Roma, J., Munell, F., Fargas, A., and Roig, M. (2004). Evolution of pathological changes in the gastrocnemius of the mdx mice correlate with utrophin and beta-dystroglycan expression. Acta Neuropathol. 108, 443-452. doi: 10.1007/s00401-004-0908-1
89. Sampaolesi, M., Blot, S., D'Antona, G., Granger, N., Tonlorenzi, R., Innocenzi, A., et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579. doi: 10.1038/nature05282
90. Sanes, J. R. (2003). The basement membrane/basal lamina of skeletal muscle. J. Biol. Chem. 278, 12601-12604. doi: 10.1074/jbc.R200027200
91. Shi, H., Verma, M., Zhang, L., Dong, C., Flavell, R. A., and Bennett, A. M. (2013). Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5. J. Clin. Invest. 123, 2064-2077. doi: 10.1172/JCI64375
92. Shin, J., Tajrishi, M. M., Ogura, Y., and Kumar, A. (2013). Wasting mechanisms in muscular dystrophy. Int. j. Biochem. cell Biol. 45, 2266-2279. doi: 10.1016/j.biocel.2013.05.001
93. Sohar, I., Laszlo, A., Gaal, K., and Mechler, F. (1988). Cysteine and metalloproteinase activities in serum of Duchenne muscular dystrophic genotypes. Biol. Chem. Hoppe-Seyler 369(Suppl.), 277-229
94. Srivastava, A. K., Qin, X., Wedhas, N., Arnush, M., Linkhart, T. A., Chadwick, R. B., et al. (2007). Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J. Biol. Chem. 282, 35113-35124. doi: 10.1074/jbc.M705329200
95. Tajrishi, M. M., Zheng, T. S., Burkly, L. C., and Kumar, A. (2014). The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev. doi: 10.1016/j.cytogfr.2013.12.004. [Epub ahead of print]
96. Taniguti, A. P., Matsumura, C. Y., Rodrigues-Simioni, L., Santo Neto, H., and Marques, M. J. (2012). Suramin affects metalloproteinase-9 activity and increases beta-dystroglycan levels in the diaphragm of the dystrophin-deficient mdx mouse. Muscle Nerve 46, 810-813. doi: 10.1002/mus.23468
97. Turpeenniemi-Hujanen, T., Thorgeirsson, U. P., Hart, I. R., Grant, S. S., and Liotta, L. A. (1985). Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J. Natl. Cancer Inst. 75, 99-103
98. Tyagi, S. C., Kumar, S. G., Haas, S. J., Reddy, H. K., Voelker, D. J., Hayden, M. R., et al. (1996). Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell. Cardiol. 28, 1415-1428. doi: 10.1006/jmcc.1996.0132
99. Vetrone, S. A., Montecino-Rodriguez, E., Kudryashova, E., Kramerova, I., Hoffman, E. P., Liu, S. D., et al. (2009). Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J. Clin. Invest. 119, 1583-1594. doi: 10.1172/JCI37662
100. von Moers, A., Zwirner, A., Reinhold, A., Bruckmann, O., van Landeghem, F., Stoltenburg-Didinger, G., et al. (2005). Increased mRNA expression of tissue inhibitors of metalloproteinase-1 and-2 in Duchenne muscular dystrophy. Acta Neuropathol. 109, 285-293. doi: 10.1007/s00401-004-0941-0
101. Vu, T. H., and Werb, Z. (2000). Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14, 2123-2133. doi: 10.1101/gad.815400
102. Wilson, W. R., Evans, J., Bell, P. R., and Thompson, M. M. (2005). HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 30, 259-262. doi: 10.1016/j.ejvs.2005.02.044
103. Wu, D., Huang, P., Wang, L., Zhou, Y., Pan, H., and Qu, P. (2013). MicroRNA-143 inhibits cell migration and invasion by targeting matrix metalloproteinase 13 in prostate cancer. Mol. Med. Rep. 8, 626-630. doi: 10.3892/mmr.2013.1501
104. Xu, D., McKee, C. M., Cao, Y., Ding, Y., Kessler, B. M., and Muschel, R. J. (2010). Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res. 70, 6988-6998. doi: 10.1158/0008-5472.CAN-10-0242
105. Xu, N., Zhang, L., Meisgen, F., Harada, M., Heilborn, J., Homey, B., et al. (2012). MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J. Biol. Chem. 287, 29899-29908. doi: 10.1074/jbc.M112.391243
106. Yasuda, S., Miyazaki, S., Kinoshita, H., Nagaya, N., Kanda, M., Goto, Y., et al. (2007). Enhanced cardiac production of matrix metalloproteinase-2 and-9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin. Sci. 112, 43-49. doi: 10.1042/CS20060110
107. Yu, Q., and Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176. doi: 10.1101/gad.14.2.163
108. Zanotti, S., Gibertini, S., and Mora, M. (2010). Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatment. Cell Tissue Res. 339, 397-410. doi: 10.1007/s00441-009-0889-4
109. Zanotti, S., Saredi, S., Ruggieri, A., Fabbri, M., Blasevich, F., Romaggi, S., et al. (2007). Altered extracellular matrix transcript expression and protein modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biol. 26, 615-624. doi: 10.1016/j.matbio.2007.06.004
110. Zhong, D., Saito, F., Saito, Y., Nakamura, A., Shimizu, T., and Matsumura, K. (2006). Characterization of the protease activity that cleaves the extracellular domain of beta-dystroglycan. Biochem. Biophys. Res. Commun. 345, 867-871. doi: 10.1016/j.bbrc.2006.05.004